#Yashoindustries Q3 Concall Highlights

Like & Retweet for better reach !

Operational Highlights

1. Revenues stood at ₹166.4Cr in Q3FY22 from ₹97.5Cr in previous year same quarter, growth of 70.7% YoY
2. EBITDA grew by 82.3% YoY to ₹28.2 Cr with EBITDA margins at 17% in Q3FY22

3. Volumes increased by 35.8% YoY to 2953 MTPA

9MFY22 Revenue contribution

1. Growth driven by the specialty segment followed by rubber and lubricants.
2. Aroma chemicals- 14%, Food antioxidants-13%, Rubber chemicals- 36%, Lubricant additives- 13% and Specialty chemicals- 24%

3. Total 148 products across these verticals
Domestic revenues stood at 38% followed by USA- 26, Europe- 22% and RoW- 14% (export revenues- 62%)
Tier1 and Tier 2 suppliers for FMCG customers like, Adani wilmar, colgate, SH kelkar, comtinenatl tyres, CEAT, mischelinen, jk tyres, indian oil, HPCL etc

Expanded capacity from 6000 MT to 11000 MT for rubber, lubricants and speciality segment
Improvement in margins will begin from Q4FY22 onwards

Current capacity utilisation is at peak of 90% (existing + part of new capacities) for 9MFY22 and continues to operate on optimal levels.
Company is evaluating opportunities for capacity expansion

Unexpected incremental cost of power and raw materials will be passed on in next quarter
Key raw materials for different verticals

1. Antioxidants- Hydroquinone & Tertbutyl alcohol
2. Aroma chemicals- Clove leaf oil (imported from Madagascar)
3. Rubber and lubricants- Carbon di-sulphide, amines & di-phenylamines
3-6 months contract with suppliers for procurement. Also having contracts with customer on quarterly to monthly basis and many other are on spot basis
FY22 revenue guidance of ₹540Cr approx.

Applied for EC and under approval process

Working in 3 segments within lubricants i.e antioxidants, corrosion inhibitors and fixer modifiers of which- lubricant is performing well, fixer modifiers approval period is longer and is
picking up well and corrosion inhibitors will be driven by the demand ramp up of ethanol blended fuel

Specialty segment products finds applications in stabilisers for monomer in acids, epoxy resin and thermoplastics
Competitors

1. Food antioxidants- Camlin fine science, Clean science, Solvay

2. Aroma chemicals- manufacturer from Indonesia because clove oil is grown mainly there
3. Rubber segment- NOCIL, LANXESS and some Chinese players

4. Lubricants- BASF , LANXESS and few competition from china

The greenfield project is under consideration and approvals are expected soon.
Moderate growth for 2022-23 and will be more into rubber, lubricants and specialty segment

Increasing R&D capacity and intend to increase R&D spending from this quarter onwards and will be focused on lubricant and rubber products
Long term debt is ₹40-45 Cr and short term debt is ₹100 Cr. Debt reduction will not be anytime soon as focus on greenfield expansion

No customers contributed more the 5% of revenues
Rubber, specialty and lubricants segment have better margins compared to food and aroma business

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

Feb 11
#SRF Q3 Concall Highlights 🧪🧪

Like & Retweet for better reach !

Operational Highlights

1. Revenues for the quarter stood at ₹3,345.9 as against ₹2146.4 Cr in Q3FY21, translating growth of 55.9% YoY

2. EBITDA margins stood at 25.7%
Revenue breakup

Chemical business-42.6%, Packaging films-38.1%, Technical textile- 16.1% and others-3.2%
Business Highlights

1. Launched new pharma intermediate during the quarter and successfully conducted campaigns for 2-3 upcoming products.

2. Achieved highest ever production in key products and are constantly enhancing capacity utilisation at newly commissioned facility
Read 16 tweets
Feb 11
#Aartiindustries Q3 concall highlights

Like & Retweet for better reach !

Operational Highlights

1. Revenues for the quarter stood at ₹2376 Cr, with a robust growth of 100.1% YoY

2. Both the Pharmaceuticals & Specialty Chemicals segment outperformed during the quarter
3. Revenue expansion during the quarter includes cost escalations passed on to the customers due to substantial increase in raw material prices as well as fuel and logistics costs
4. Accrual of termination fees in respect of the long-term contract of ₹631 crores resulting in higher revenues. As a result, EBITDA includes ₹611 Crs during the quarter.
Read 18 tweets
Feb 11
#SHKelkar Q3 2022 Concall Highlights

Like & Retweet for better reach !

Operational Highlights

1. Revenues from operations stood at Rs. 396.6 crore in Q3FY22 as against Rs. 375.4 crore in Q3FY21, higher by 5.6%
2. EBITDA margins remained stable on a sequential basis at 15.8% translating to EBITDA of 63.8 crore

3. Gross margins in 9M FY22 stood at 41.4%

4. Q3 FY22 revenues growth was driven on the back of rebound in consumer demand led by discretionary items and new client wins.
5. While the domestic core fragrance segment delivered healthy performance, sales in Southeast Asia region continued to be affected by the Covid surge and is yet to recover
Read 19 tweets
Feb 11
#AurobindoPharma Q3 FY22 concall highlights 💊💊

Like & retweet for better reach !

1. Revenues for the quarter stood at ₹6002 Cr (1% decline YoY).
2. EBITDA was at ₹1016 Cr (20% decline YoY) for the quarter. EBITDA margins for the quarter were 16.9%. PAT stood at ₹604.3 Cr (80% decline YoY).
3. Revenue from formulations was ₹4992 Cr (12% decline YoY).

4. Formulations contributed about 83% of total revenues. Revenue from the API business stood at ₹1010 Cr (48% growth YoY) and contributed about 17% of revenues.
Read 18 tweets
Feb 11
#HesterBiosciences Q3 FY22 concall highlights 🐓🐓

Like & Retweet for better reach !

1. Revenues are flat and profitability is down because of the high base effect.
2. Q3 and Q4 of FY21 were phenomenal quarters for the company because there was a major poultry disease outbreak which led to increased demand for vaccines.

3. They also have additional income every year from licensing fees which is not there in Q3 FY22.
4. They have been working on 3 vaccines - classical swine fever, lumpy skin disease and sheep pox vaccine. All these vaccines are in the final stages of quality testing and regulatory approval and they hope to launch them in Q1 FY23.
Read 14 tweets
Feb 11
#AlembicPharma Q3 FY22 concall highlights

Like & Retweet for better reach !

1. Revenues for the quarter stood at ₹1272 Cr (3% decline YoY).

2. EBITDA for the quarter was ₹269 Cr (33% decline YoY). EBITDA margin was at 21% for the quarter.
3. PAT stood at 176 Cr (40% decline YoY).

4. They believe the price erosion in the US business has normalized and they can grow with new launches from here on.
5. They have a couple of first-to-file launches coming up in FY23.

6. R&D expenditure for the quarter was at ₹154 Cr which is about 12% of sales. They have filed 6 ANDAs during the quarter.
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

:(